All In Biotech

Drug Trial Radar · NCT00408005

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,895 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,895

Actual

Start

Jan 30, 2007

Primary completion

Sep 30, 2017

Study completion Mar 31, 2025

Sponsor

Sponsor type
NIH
First posted
Dec 5, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. After a common induction therapy, patients were risk assigned and eligible for one or both post-induction randomizations: Escalating dose Methotrexate versus High Dose Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High Risk and induction failures. Standard risk patients did not receive nelarabine, High risk T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures were assigned to receive Nelarabine.

Conditions

  • T Acute Lymphoblastic Leukemia
  • T Lymphoblastic Lymphoma

Interventions

  • AsparaginaseDrug

    Given IM or IV

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IT, IV, or SC

  • Daunorubicin HydrochlorideDrug

    Given IV

  • DexamethasoneDrug

    Given IV or PO

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Leucovorin CalciumDrug

    Given PO

  • MercaptopurineDrug

    Given PO

  • MethotrexateDrug

    Given IT or PO

  • NelarabineDrug

    Given IV

  • PegaspargaseDrug

    Given IM or IV

  • PrednisoneDrug

    Given IV or PO

  • Radiation TherapyRadiation

    Some patients undergo testicular and/or prophylactic cranial RT

  • ThioguanineDrug

    Given PO

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)Time frame: 4 years from randomization at the end of induction
  2. Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)Time frame: 4 years from randomization at the end of induction
  3. Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)Time frame: 4 years from randomization at the end of induction
  4. Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)Time frame: 4 years from randomization at the end of induction
  5. Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) CohortTime frame: 4 years from end of induction

Locations

215 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • USA Health Strada Patient Care Center

    Mobile, Alabama

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Lee Memorial Health System

    Fort Myers, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • Miami Cancer Institute

    Miami, Florida

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.